Conor expands COSTAR II
This article was originally published in The Gray Sheet
Executive Summary
FDA approves Conor Medsystem's plan to expand enrollment of the COSTAR II U.S. pivotal trial of the CoStar cobalt chromium paclitaxel-eluting stent to 85 sites and 1,700 patients. An initial IDE for the trial was approved by FDA in March. The trial randomizes patients with single or multi-vessel de novo coronary lesions to receive either CoStar or Boston Scientific's Taxus paclitaxel-eluting stent. CoStar is available in Europe and India...